(3H)maraviroc
Spezifikationen
376348-65-1CAS-Nummer
4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamideIUPAC-Name
C29H41F2N5OChemische Formel
513.7 g/molMolekulargewicht
(3H)maraviroc; [3H]maraviroc; RefChem:1050229; Maraviroc; 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; MD6P741W8A; C29H41F2N5O; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEMBL256907; CHEMBL584744; MVC; CHEMBL1201187; DTXSID8048949; CHEBI:63608; 4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; Cyclohexanecarboxamide,4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; NCGC00183109-02; 2414315-81-2; 4,4-difluoro-N-[(1S)-3-[(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Celsentri(TM); Selzentry(TM); 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1s)-3-{(3-Exo)-3-[3-Methyl-5-(Propan-2-Yl)-4h-1,2,4-Triazol-4-Yl]-8-Azabicyclo[3.2.1]oct-8-Yl}-1-Phenylpropyl]cyclohexanecarboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-; PRO 140 & Maraviroc; maravirocum; Maraviroc [INN:BAN:JAN]; UNII-MD6P741W8A; Rel-Maraviroc; HSDB 8021; Maraviroc, endo-; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-{(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; UK-427,857 maraviroc (MVC); MARAVIROC [INN]; MARAVIROC [JAN]; MARAVIROC [MI]; [3H]UK 427,857; [3H]UK-427,857; MARAVIROC [VANDF]; A3C7SRV8DV; Epitope ID:231724; MARAVIROC [MART.]; MARAVIROC [WHO-DD]; SCHEMBL51991; Selzentry, UK 427857; GTPL803; GTPL806; MARAVIROC [EMA EPAR]; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MLS006011960; orb1301149; SCHEMBL2177194; SCHEMBL4576508; MARAVIROC [ORANGE BOOK]; DTXCID5028875; Maraviroc, >=98% (HPLC); EX-A200; CHEBI:184662; GSNHKUDZZFZSJB-HLMSNRGBSA-N; GSNHKUDZZFZSJB-QUMGSSFMSA-N; GLXC-90148; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; Tox21_113369; AC-558; BDBM50334986; BDBM50464147; BDBM50583789; EBC-11333; EBC-14811; EBC-27258; MFCD13188530; MFCD31536297; AKOS025402143; AKOS032946723; AKOS032960315; UK 427857-d6; CS-0366; DB04835; FM25017; NCGC00183109-01; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; AS-75265; exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; HY-13004; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; SMR004703532; CAS-376348-65-1; T6016; EN300-128501; EN300-7367238; EN300-22828861; F868938; Q421369; SR-01000942244; SR-01000942244-1; BRD-A23284911-001-02-4; Z1614451557; 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide; 4,4-difluoro-N-((1S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-((1R,3S,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-((S)-3-((1S,3S,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,3R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid; 4,4-Difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl-d6)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl] cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane-8-yl]-1-phenylpropyl]cyclohexane1-formamide; 4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide; 4,4-diluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; MRVSynonyme
Produkte, die (3H)maraviroc enthalten
MARAVIROC WAYMADE 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC WAYMADE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC TARBIS 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC TARBIS 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGCELSENTRI 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULACELSENTRI 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMARAVIROC WAYMADE 300 mg, comprimé pelliculéMARAVIROC WAYMADE 150 mg, comprimé pelliculéCELSENTRI 75 mg, comprimé pelliculéCELSENTRI 300 mg, comprimé pelliculéCELSENTRI 25 mg, comprimé pelliculéCELSENTRI 20 mg/ml, solution buvable
Seite 1 von 2
Unternehmen, die (3H)maraviroc verkaufen
JM
Jiangsu Magic Biotechnology Co., LtdChinaTF
Tarbis Farma S.L.SpainVH
Viiv Healthcare B.V.NetherlandsWB
Waymade B.V.NetherlandsLC
LEAP CHEM CO., LTD.Seite 1 von 2